Incidence and Risk Factors for Pulmonary Exacerbation Treatment Failures in Patients With Cystic Fibrosis Chronically Infected With Pseudomonas aeruginosa

CHEST Journal ◽  
2012 ◽  
Vol 141 (2) ◽  
pp. 485-493 ◽  
Author(s):  
Michael D. Parkins ◽  
Jacqueline C. Rendall ◽  
J. Stuart Elborn
Keyword(s):  
Risk Factors ◽  
Cystic Fibrosis ◽  
Pseudomonas Aeruginosa ◽  
Pulmonary Exacerbation

scholarly journals Incidence and risk factors for frequent pulmonary exacerbation in cystic fibrosis

2010 ◽  
Vol 9 ◽  
pp. S110 ◽  
Author(s):  
M.D. Parkins ◽  
M. Ibrahim ◽  
J.C. Rendall ◽  
J.S. Elborn
Keyword(s):  
Risk Factors ◽  
Cystic Fibrosis ◽  
Pulmonary Exacerbation

Application of quantitative PCR to the diagnosis and monitoring of Pseudomonas aeruginosa colonization in 5–18-year-old cystic fibrosis patients

2011 ◽  
Vol 60 (2) ◽  
pp. 157-161 ◽  
Author(s):  
Typhaine Billard-Pomares ◽  
Stéphanie Herwegh ◽  
Nathalie Wizla-Derambure ◽  
Dominique Turck ◽  
René Courcol ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Pseudomonas Aeruginosa ◽  
Quantitative Pcr ◽  
Sputum Sample ◽  
Pulmonary Exacerbation ◽  
Additional Tool ◽  
Bacterial Cultures ◽  
Group A ◽  
Group B ◽  
Age Range

Early detection of Pseudomonas aeruginosa and early aggressive treatment are recommended to delay chronic infection in cystic fibrosis (CF) patients. The aim of this study was to assess a quantitative PCR (q-PCR) assay for the diagnosis of early P. aeruginosa colonization in 23 young CF patients (group A, age range 7–18 years) and to survey the eradication of P. aeruginosa in 10 young CF patients (group B, age range 5–18 years) after an initial antibiotic treatment. q-PCR results for consecutive sputum samples from each patient during a period of 18 months were compared with bacterial cultures during the same period plus an additional period of 12 months, and with concomitant clinical signs of pulmonary exacerbation. The q-PCR and bacterial cultures were negative for 17 of the 23 patients in group A and six of the 10 patients in group B during the study period. However, consecutive positive q-PCR results were observed for one patient in group A and three patients in group B, while the bacterial cultures for the same sputum sample remained negative. They preceded positive P. aeruginosa bacterial cultures at 7 and 8 months for two patients in group B. These positive results were associated with a worsening of the clinical status of patients, but pulmonary exacerbation appeared non-specific for the diagnosis of early P. aeruginosa colonization since pulmonary exacerbations were observed in patients in whom q-PCR or bacterial culture remained negative. In conclusion, q-PCR may be a useful additional tool to provide information on the P. aeruginosa status of CF patients.

Risk factors leading to pulmonary exacerbation in patients with cystic fibrosis: A systematic review

2021 ◽  
Vol 71 (9) ◽  
Author(s):  
Danish Abdul Aziz ◽  
Syeda Khadija Fatima ◽  
Hasan Nawaz Tahir
Keyword(s):  
Risk Factors ◽  
Systematic Review ◽  
Cystic Fibrosis ◽  
Meta Analysis ◽  
Nutritional Deficiencies ◽  
Pulmonary Exacerbation ◽  
Case Control Studies ◽  
Cross Sectional ◽  
Factors Associated ◽  
Randomised Controlled

Objective: To ascertain major risk factors associated with pulmonary exacerbation and pulmonary function decline in cystic fibrosis. Method: The systematic review was conducted at Aga Khan University, Karachi, in September 2018, and comprised electronic search of PubMed, Ovid, Science Direct and Cumulative Index of Nursing and Allied Health Literature databases of studies conducted from January 1990 to September 2018 which were categorised into 3 sets; 1990-98, 1999-2007 and 2008-18. Studies included for review focussed on articles with pulmonary exacerbation as the health outcome indicator, and had diagnosis of cystic fibrosis as the inclusion criteria, while risk factors were the exposure terms used in the search process. References in bibliographies of the included studies were also systematically searched for relevant documents. Results: Of the 60 studies obtained, 31(51.7%) were selected; 2(6.45%) from 1990-98, 7(22.58%) from 1999-2007 and 22(70.96%) from 2008-18. Overall, 17(54.83%) were cohort studies, 7(22.5%) were cross-sectional studies, 3(9.6%) were case-control studies, 3(9.6%) were randomised controlled trials and 1(3.2%) was systematic review and meta-analysis. In terms of major risk factors, genetic mutations were cited by 4(12.9%) studies, infections and inflammatory biomarkers by 15(48.4%), nutritional deficiencies by 9(29%) and geographical and socioeconomic status by 3(9.6%) studies. Conclusion: Early identification and recognition of risk factors associated with pulmonary exacerbation can have an explicit impact on its management, leading to decreased morbidity and mortality burden in cystic fibrosis cases. Key Words: Pulmonary exacerbation, Cystic fibrosis, Risk factors, Systematic review. Continuous...

INCIDENCE AND RISK FACTORS FOR MULTIPLE ANTIBIOTIC RESISTANT PSEUDOMONAS AERUGINOSA (MARPA) IN CYSTIC FIBROSIS

CHEST Journal ◽  
2005 ◽  
Vol 128 (4) ◽  
pp. 152S
Author(s):  
Christian A. Merlo ◽  
Michael P. Boyle ◽  
Marie Diener-West ◽  
Noah Lechtzin
Keyword(s):  
Risk Factors ◽  
Cystic Fibrosis ◽  
Pseudomonas Aeruginosa ◽  
Antibiotic Resistant

scholarly journals Risk factors for lung disease progression in children with cystic fibrosis

2018 ◽  
Vol 51 (6) ◽  
pp. 1702509 ◽  
Author(s):  
Marieke van Horck ◽  
Kim van de Kant ◽  
Bjorn Winkens ◽  
Geertjan Wesseling ◽  
Vincent Gulmans ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cystic Fibrosis ◽  
Lung Disease ◽  
Disease Progression ◽  
Potential Risk ◽  
Allergic Bronchopulmonary Aspergillosis ◽  
Pulmonary Exacerbation ◽  
Exacerbation Rate ◽  
Potential Risk Factors ◽  
Pulmonary Exacerbations

To identify potential risk factors for lung disease progression in children with cystic fibrosis (CF), we studied the longitudinal data of all children with CF (aged ≥5 years) registered in the Dutch CF Registry (2009–2014).Lung disease progression was expressed as a decline in lung function (forced expiratory volume in 1 s (FEV1) % pred) and pulmonary exacerbation rate. Potential risk factors at baseline included sex, age, best FEV1 % pred, best forced vital capacity % pred, genotype, body mass index z-score, pancreatic insufficiency, medication use (proton pump inhibitors (PPIs), prophylactic antibiotics and inhaled corticosteroids), CF-related diabetes, allergic bronchopulmonary aspergillosis and colonisation with Pseudomonas aeruginosa.The data of 545 children were analysed. PPI use was associated with both annual decline of FEV1 % pred (p=0.017) and future pulmonary exacerbation rate (p=0.006). Moreover, lower FEV1 % pred at baseline (p=0.007), prophylactic inhaled antibiotic use (p=0.006) and pulmonary exacerbations in the baseline year (p=0.002) were related to pulmonary exacerbations in subsequent years.In a cohort of Dutch children with CF followed for 5 years, we were able to identify several risk factors for future exacerbations. In particular, the association between PPI use and lung disease progression definitely requires further investigation.

Energetic cost of physical activity in cystic fibrosis children during Pseudomonas aeruginosa pulmonary exacerbation

2005 ◽  
Vol 24 (1) ◽  
pp. 88-96 ◽  
Author(s):  
L. Béghin ◽  
F. Gottrand ◽  
L. Michaud ◽  
H. Vodougnon ◽  
N. Wizla-Derambure ◽  
...  
Keyword(s):  
Physical Activity ◽  
Cystic Fibrosis ◽  
Pseudomonas Aeruginosa ◽  
Energetic Cost ◽  
Pulmonary Exacerbation
Sign in / Sign up

Export Citation Format

Share Document